Adicet opens ADI-270 Phase 1 enrollment in ccRCC, doses first lupus nephritis patient with ADI-001

Adicet Bio, Inc.

Enrollment opened for Phase 1 trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma; preliminary data expected 1H25.
First lupus nephritis patient dosed in Phase 1 trial of ADI-001; preliminary clinical data in LN anticipated 1H25.
ADI-001 received FDA Fast Track Designation for relapsed/refractory class III or IV lupus nephritis.
Company expects to begin enrollment in SLE, SSc, IIM, SPS in 1Q25 and AAV in 2H25.
ADI-270 is the first gamma delta CAR T cell therapy for solid tumors to enter clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.